MedPath
Found 20 clinical trials|View Analysis
Sort by:

CT-95 in Advanced Cancers Associated with Mesothelin Expression

Phase 1
Recruiting
Conditions
Mesothelin-Expressing Tumors
Epithelial Ovarian Cancer
Malignant Pleural Mesothelioma, Advanced
Malignant Peritoneal Mesothelioma, Advanced
Pancreatic Adenocarcinoma Advanced or Metastatic
Lung Adenocarcinoma Metastatic
Cholangiocarcinoma Advanced
Cholangiocarcinoma Non-resectable
Mesothelin-expressing Advanced Cancers
Mesothelin-positive Advanced Malignant Solid Tumors
Interventions
Drug: CT-95
First Posted Date
2025-01-01
Last Posted Date
2025-01-01
Lead Sponsor
Context Therapeutics Inc.
Target Recruit Count
50
Registration Number
NCT06756035
Locations
🇺🇸

Context Investigational Site, San Antonio, Texas, United States

A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

Not Applicable
Recruiting
Conditions
Mesothelin Positive Tumors
Interventions
Biological: CHT102 allogeneic CAR T cells
First Posted Date
2024-12-04
Last Posted Date
2024-12-04
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
24
Registration Number
NCT06717022
Locations
🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Phase 1
Recruiting
Conditions
Mesothelin Positive
Mesothelin-Expressing Tumors
Esophageal Adenocarcinoma
Esophageal Adenocarcinomas
Esophagogastric Adenocarcinoma
Peritoneal Carcinomatosis
Breast Neoplasms
Diabetes Mellitus
Interventions
Biological: M28z1XXPD1DNR CAR
First Posted Date
2024-10-02
Last Posted Date
2024-10-03
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
18
Registration Number
NCT06623396
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Phase 1
Recruiting
Conditions
Malignant Mesothelioma
Ovary Cancer
Breast Cancer Female
Bile Duct Cancer
Pancreatic Cancer
Colorectal Cancer
Rectal Cancer
Interventions
Biological: UCMYM802 Injection
First Posted Date
2024-02-13
Last Posted Date
2024-07-24
Lead Sponsor
UTC Therapeutics Inc.
Target Recruit Count
24
Registration Number
NCT06256055
Locations
🇨🇳

Peking University Cancer Hospital & Institute, Beijing, China

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Phase 1
Recruiting
Conditions
Mesothelin-positive Advanced Malignant Solid Tumors
Interventions
Biological: UCLM802 Cell Injection (Anti-mesothelin CAR-T cells)
First Posted Date
2023-05-08
Last Posted Date
2023-05-12
Lead Sponsor
Zhejiang University
Target Recruit Count
87
Registration Number
NCT05848999
Locations
🇨🇳

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

MSLN-targeted CAR-T Cells in Solid Tumors.

Phase 1
Not yet recruiting
Conditions
Mesothelin-positive Advanced Malignant Solid Tumors
Interventions
Biological: Anti-mesothelin CAR-T cells
First Posted Date
2023-03-24
Last Posted Date
2023-03-24
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
87
Registration Number
NCT05783089

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Phase 1
Not yet recruiting
Conditions
Solid Tumor
Interventions
Biological: UCLM802 Cell Injection
First Posted Date
2023-03-20
Last Posted Date
2023-03-20
Lead Sponsor
Peking University
Target Recruit Count
87
Registration Number
NCT05775666

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Phase 1
Withdrawn
Conditions
Mesothelin-positive Advanced Refractory Solid Tumors
Interventions
Biological: Anti-mesothelin CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2022-09-08
Last Posted Date
2023-03-01
Lead Sponsor
Shanghai Pudong Hospital
Registration Number
NCT05531708
Locations
🇨🇳

Shanghai Pudong Hospital, Fudan University Affiliated Pudong Medical Center, Shanghai, Shanghai, China

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

Not Applicable
Completed
Conditions
Ovarian Cancer
Interventions
Drug: mesothelin-specific chimeric antigen receptor T cell injection
First Posted Date
2022-05-13
Last Posted Date
2023-07-17
Lead Sponsor
Weijia Fang, MD
Target Recruit Count
3
Registration Number
NCT05372692
Locations
🇨🇳

First affiliated hospital, School of Medicine, Zhejiang University, Hangzhou, China

Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors

Phase 1
Conditions
Solid Tumor, Adult
Interventions
Biological: Mesothelin-directed CAR-T cells
First Posted Date
2018-11-20
Last Posted Date
2018-11-20
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
10
Registration Number
NCT03747965
Locations
🇨🇳

Chinese PLA General Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath